Mobile DR Screening Using Cellphones

Image, screen, and view results all on the smartphone

  • Need for EyeApp

    Studies show that in 90% of cases of vision loss can be prevented if DR is diagnosed at an early stage. Since DR progresses without any pain or discomfort, screening every diabetic for DR via retinal imaging or examination is the only way to identify patients for treatment. In order to screen the estimated 371 million diabetics worldwide for preventable blindness due to DR, and for this screening to scale as the diabetic population grows to over 550 million by the year 2030, computerized diabetic retinopathy screening must be deployed at massive scales and made accessible.
    • icon
      Image Analysis
    • image
    • icon
      Cellphone Imaging
    • image
    • icon
      EyeApp
    image
  • What is EyeApp?

    EyeApp is designed to enable any health care provider to conduct diabetic retinopathy screening via a cellphone, without need for a costly fundus camera. This technology offers the potential to greatly increase the number of patients that can be screened and reduce blindness due to diabetic retinopathy (DR).

    The end-to-end EyeApp technology combines a small, mobile, retinal imaging camera (Ocular CellScope) that attaches to a smartphone with software providing fully automated screening, grading and reporting with high sensitivity and specificity. This mobile capability makes screening much easier for senior patients whose mobility is limited, accommodating itself to the patient rather than the patient having to accommodate a typical fundus camera.

icon Technology behind EyeApp

Our image analysis algorithms represent cutting-edge of research in image processing, computer vision, and machine learning. Technological innovations like morphology-inspired filter bank descriptors can automatically analyze fundus images to detect and localize lesions resulting from diabetic retinopathy. Combined with deep learning techniques, they can help accurately triage patients at risk of vision loss due to diabetic retinopathy.

Signup to stay up-to-date on Eyenuk's products!



* This product was supported by Award numbers R44EB013585, R42TR000377, R43EY024848, and R43EY025984 from the National Institutes of Health (NIH). The content is solely the responsibility of Eyenuk, Inc. and does not necessariliy represent the official views of NIH.
** This device is covered by one or more of the following US patents and their foreign counterparts: 8879813, 8885901, 9002085, and 9008391. Additional patents are pending.

EyeApp™ has not yet been cleared for sales in the US or EU.

Ocular CellScope is being developed by Prof. Daniel Fletcher, PhD (University of California, Berkeley), Dr. Todd Margolis, MD, PhD (Washington University School of Medicine in St Louis) and others.